DOH, FDA: NO REASON TO HALT ASTRAZENECA VACCINATION IN PH; BENEFITS CONTINUE TO OUTWEIGH RISKS

Press Release | 12 March 2021

The DOH and FDA are aware that a few countries in the European Union have recently paused their vaccination campaign with COVID-19 vaccine AstraZeneca following reports of blood clots in people who received the vaccine. This has been decided as a precautionary measure, while they conduct a full investigation to determine causality between the vaccination and the reported adverse events following immunization.

Moreover, the European Medicine Authority (EMA) has also emphasized that there is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine, saying, “The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing. PRAC is already reviewing all cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination with COVID-19 Vaccine AstraZeneca.”

At present, the DOH and FDA emphasize that there is no indication for the Philippines to stop rollout of AstraZeneca vaccines. The DOH, NTF and FDA are closely coordinating on this matter. The public is assured they will closely monitor all deployed vaccines.